[ Back to EurekAlert! ] Public release date: 7-Sep-2011
[ | E-mail Share Share ]

Contact: Tasheema Prince
niaidnews@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases

Researchers Discuss Challenges to Developing Broadly Protective HIV Vaccines

New Advances Provide Reason for Optimism

The human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not produced in an efficient or timely enough fashion in HIV-infected individuals to effectively block progression of infection, appearing only after a person has been infected with HIV for at least one year -- by which time the virus has fully established itself within the body. In a Perspective article appearing this week in the New England Journal of Medicine, scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, assert that a key research goal is to develop HIV vaccines that prevent HIV infection by inducing more effective immune responses than those that occur naturally.

In their article, the authors examine the challenges of developing HIV vaccines that can effectively induce these broadly neutralizing antibodies. Specifically, they describe work under way to design structure-based HIV vaccines, as well as efforts to gain a better understanding of the evolutionary processes that human B cells undergo to produce broadly neutralizing HIV antibodies. The authors conclude that the availability of new research tools, together with the increased understanding of the human immune response to HIV, make them optimistic that an HIV vaccine that provides significant protection against acquisition of HIV infection can be achieved.

###

ARTICLE:
MI Johnston and AS Fauci. HIV Vaccine Development – Improving on Natural Immunity. New England Journal of Medicine DOI: 10.1056/NEJMp1107621 (2011).

WHO:
NIAID Director Anthony S. Fauci, M.D., co-author of the paper, is available to discuss the article.

CONTACT:
To schedule interviews, please contact Tasheema Prince at (301) 402-1663 or niaidnews@niaid.nih.gov.

NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at http://www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.